Non-Hodgkin lymphoma

[1]  L. Staudt,et al.  Mechanisms of Disease , 2010 .

[2]  İrfan Yavaşoğlu,et al.  Follicular Lymphoma , 2015, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[3]  R. Advani,et al.  Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update , 2011 .

[4]  W. Wierda,et al.  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.

[5]  S. Pileri,et al.  Anaplastic large-cell lymphoma. , 2011, Seminars in diagnostic pathology.

[6]  J. Pinilla-Ibarz,et al.  Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. , 2011, Clinical lymphoma, myeloma & leukemia.

[7]  M. Ghielmini,et al.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Salles,et al.  Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. , 2010 .

[9]  G. Fingerle-Rowson,et al.  Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised , open-label , phase 3 trial , 2010 .

[10]  M. Djokic.  ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project , 2009 .

[11]  W. R. Burack,et al.  The incidence, natural history, biology, and treatment of transformed lymphomas. , 2009, Hematology. American Society of Hematology. Education Program.

[12]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[13]  A. Hagenbeek,et al.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Horning.  Follicular lymphoma, survival, and rituximab: is it time to declare victory? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[17]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Gaulard,et al.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.

[19]  T. Robak,et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Cyster,et al.  Germinal-center organization and cellular dynamics. , 2007, Immunity.

[21]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[25]  David Jung,et al.  Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. , 2006, Annual review of immunology.

[26]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[27]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Gressin,et al.  High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. , 2005, Blood.

[31]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[32]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[34]  W. Hiddemann,et al.  Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Kerl,et al.  Borrelia burgdorferi‐associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases , 2004, Journal of cutaneous pathology.

[36]  K. Maclennan,et al.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.

[37]  B. Hancock,et al.  Non-Hodgkin lymphoma , 2003, The Lancet.

[38]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[39]  S. Pileri,et al.  Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Siebert,et al.  Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  N. Schmitz,et al.  Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Taniwaki,et al.  Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  A. Santoro,et al.  Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[45]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. Molina,et al.  Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[48]  S. Glaser,et al.  Changing incidence of non‐Hodgkin lymphomas in the United States , 2002, Cancer.

[49]  F. Cavalli,et al.  Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. , 2002, Blood.

[50]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[52]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[54]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[55]  P. Feugier,et al.  Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.

[56]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  E. Engleman,et al.  Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  B. Hancock.  Management of patients with lymphoma: the way forward. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[59]  M. Tiemann,et al.  Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. , 2001, Blood.

[60]  J Kotzerke,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[61]  E. Vitetta,et al.  Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.

[62]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  G. Morgan,et al.  The Effective Management of Non-Hodgkin's Lymphoma , 2001 .

[64]  W. Chan,et al.  New approaches to lymphoma diagnosis. , 2001, Hematology. American Society of Hematology. Education Program.

[65]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[66]  W. Hiddemann,et al.  IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group , 2000, Annals of Hematology.

[67]  P. Gaulard,et al.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[69]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  K. Naresh,et al.  Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  F. Gherlinzoni,et al.  The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  H. Kantarjian,et al.  Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  P. Marynen,et al.  The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. , 1999, Blood.

[74]  J. Coebergh,et al.  The rise in incidence of lymphomas in Europe 1985-1992. , 1999, European journal of cancer.

[75]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[76]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Robinson,et al.  Localised non-Hodgkin's lymphoma: the Sheffield Lymphoma Group experience (1970-1995). , 1998, International journal of oncology.

[78]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[83]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[85]  B. Coiffier,et al.  A multivariate analysis of the survival of patients with aggressive lymphoma , 1998 .

[86]  B. Coiffier,et al.  A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. , 1998, Cancer.

[87]  L. White,et al.  MR imaging of primary lymphoma of bone: variability of T2-weighted signal intensity. , 1998, AJR. American journal of roentgenology.

[88]  L. Deangelis,et al.  Long-term survival in primary CNS lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  R. Doci,et al.  Staging and Prognostic Factors , 1998 .

[90]  A. Glass,et al.  The national cancer data base report on non‐hodgkin's lymphoma , 1997, Cancer.

[91]  S. Pittaluga,et al.  The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non‐intensive therapy by the British National Lymphoma Investigation Group , 1997, British journal of haematology.

[92]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[93]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[94]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[95]  B. Johansson,et al.  A breakpoint map of recurrent chromosomal rearrangements in human neoplasia , 1997, Nature Genetics.

[96]  D. Shibata,et al.  Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. , 1997, Blood.

[97]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[98]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.

[99]  D. Weisenburger,et al.  Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin. , 1996, The American journal of surgical pathology.

[100]  M. M. Mac Manus,et al.  Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  E. Jaffe,et al.  Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  H. Tilly,et al.  Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[104]  A. Horwich,et al.  Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[105]  M. Stolte,et al.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection , 1995, The Lancet.

[106]  J. Cox,et al.  Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[108]  T. Lister,et al.  Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  J. Eshleman,et al.  Microsatellite instability in inherited and sporadic neoplasms. , 1995, Current opinion in oncology.

[110]  B. Ciffier.  What treatment for elderly patients with aggressive lymphoma , 1994 .

[111]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[112]  K. Maclennan,et al.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. , 1994, British Journal of Cancer.

[113]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[114]  M. Kaminski,et al.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.

[115]  B. Coiffier.  What treatment for elderly patients with aggressive lymphoma? , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  E. Abella,et al.  Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. , 1994, Blood.

[117]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[118]  T. C. Diss,et al.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori , 1993, The Lancet.

[119]  James R. Anderson,et al.  Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  G. Bonadonna,et al.  Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  S. Pileri,et al.  Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. , 1993, Medical and pediatric oncology.

[122]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[123]  T. Fears,et al.  Non-Hodgkin's lymphoma time trends: United States and international data. , 1992, Cancer research.

[124]  Prof. Dr. Dr. h.c. mult. Karl Lennert,et al.  Histopathology of Non-Hodgkin’s Lymphomas , 1992, Springer Berlin Heidelberg.

[125]  M. Oken,et al.  Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  S. Gillies,et al.  Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. , 1990, Journal of immunology.

[127]  B. Grosbois,et al.  A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia , 1990 .

[128]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[129]  M. Shipp,et al.  Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  B. Nathwani,et al.  Peripheral T‐cell lymphoma , 1989, Cancer.

[131]  D. Weisenburger,et al.  The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  J. Armitage,et al.  Interpretation of clinical trials in diffuse large-cell lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  J. Ironside,et al.  Primary intracerebral lymphoma: a clinicopathological analysis of 14 patients presenting over a 10-year period in Sheffield. , 1988, The Quarterly journal of medicine.

[134]  R. R. Robinson,et al.  Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. , 1987, Journal of immunology.

[135]  J. Connors,et al.  Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. , 1987, Annals of internal medicine.

[136]  M. Gospodarowicz,et al.  Patterns of disease in localized extranodal lymphomas. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  T. Miller,et al.  Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[139]  S. Rosenberg.  Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. , 1985, Journal of Clinical Oncology.

[140]  R. Mitchell,et al.  Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  N. Nissen,et al.  A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I‐II non‐hodgkin's lymphomas , 2006, Cancer.

[142]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[143]  G. Bonadonna,et al.  Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. , 1980, International journal of radiation oncology, biology, physics.

[144]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[145]  L. Craver,et al.  The diagnosis of Hodgkin's disease by aspiration biopsy. , 1946, Blood.